the aid library

Filter

826

Antimicrobial stewardship: changing risk-related behaviours in the general population

National Institut for Health and Care Excellence NICE (2017) C2

This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includesmeasures to prevent and control infection that can stop peopl ... more

Guidelines for Pharmacovigilance and Medicine Information in Rwanda (2016)

Ministry of Health, Rwanda (2016) C2

These guidelines for the National Pharmacovigilance and Medicine Information System in Rwanda have been developed to ensure that safe, efficacious and quality medicines are made available to all Rwa ... more

The fight against fake drugs by NAFDAC in Nigeria

The fight against fake drugs by NAFDAC in Nigeria Olike Chinwendu KIT (Royal Tropical Institute) Development Policy & Practice Vrije Universiteit Amsterdam (2008) CC

Review over the work and challenges of the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) in combatting counterfeiting of medicines in Nigeria.

The Importance of Pharmacovigilance

World Health Organization WHO (2020) C_WHO

The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging partic ... more

Rwanda: MOH GUIDELINES ON SUBMISSION OF DOCUMENTATION FOR REGISTRATION OF HUMAN PHARMACEUTICAL PRODUCTS

Ministry of Health, Rwanda (2014) C2

These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and ... more

WHO good manufacturing practices for pharmaceutical products: main principles

World Health Organization WHO (2014) C_WHO

Licensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP ... more

Safety Monitoring of medicinal products

Uppsala Monitoring Centre World Health Organization (2012) C_WHO

Reporting system for the general public - This document aims to provide practical guidelines on how to set up national systems for consumers to report adverse reactions to medicines. The purpose is ... more

Using indicators to measure country pharmaceutical situations

WHO World Health Organization (WHO) (2006) C_WHO

Fact Book on WHO Level I and Level II monitoring indicators - To monitor the progress of efforts to improve the global medicines situation, WHO has developed a system of indicators that measure important aspects of a country’s pharmaceutical situa ... more

Guidelines for the production, control and regulation of snake antivenom immunoglobulins

World Health Organization (World Health Organization World Health Organization WHO) (2017) C_WHO

Replacement of Annex 2 of WHO Technical Report Series, No. 964 ... more

Worldwide country situation analysis: response to antimicrobial resistance

World Health Organization (2015) C_WHO

A survey was conducted in countries in all six WHO regions and focused on the building blocks that are considered prerequisites to combat antimicrobial resistance: a comprehensive national plan, laboratory capacity to undertake surveillance for resi ... more

WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants

World Health Organization (WHO) (2003) C_WHO

The main objectives of these guidelines are to:
1. contribute to the quality assurance of medicinal plant materials used as the source for herbal medicines to improve the quality, safety and efficacy of finished herbal products; 2. guide the f ... more

Accelerating access to hepatitis C diagnostics and treatment

World Health Organization WHO (2021) C2

Overcoming barriers in low- and middle-income countries For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha ... more

Code of Practice to minimize and contain Antimicrobial Resistance WHO and FAO

Food and Agriculture Organization of the United Nations FAO, World Health Organization WHO (2021) C_WHO

This document provides additional guidance for the responsible and prudent use of antimicrobials in food-producing animals, and should be read in conjunction with the Recommended International Code of Practice for Control of the Use of Veterinary Drugs CAC/RCP 38-1993. Its obj ... more

Africa’s Health Financing in a New Era

Africa Centres for Disease Control and Prevention (Africa CDC) (2025) CC

Africa’s health sector is facing an unprecedented financing crisis, driven by a sharp decline of 70% in Official Development Assistance (ODA) from 2021 to 2025 and deep-rooted structural vulnerabilities. This collapse is placing immense pressure on Africa’s already fragile health systems as ODA ... is seen as the backbone of critical health programs: pandemic preparedness, maternal and child health services, disease control programs are all at risk, threatening Sustainable Development Goal 3 and Universal Health Coverage. Compounding this is Africa’s spiraling debt, with countries expected to service USD 81 billion by 2025—surpassing anticipated external financing inflows—further eroding fiscal space for health investments. Level of domestic resources is low. TThe Abuja Declaration of 2001, a pivotal commitment made by African Union (AU) member states, aimed to reverse this trend by pledging to allocate at least 15% of national budgets to the health sector. However, more than two decades later, only three countries—Rwanda, Botswana, and Cabo Verde—have consistently met or exceeded this target (WHO, 2023). In contrast, over 30 AU member states remain well below the 10% benchmark, with some allocating as little as 5–7% of their national budgets to health. In addition, only 16 (29%) of African countries currently have updated versions of National Health Development Plan (NHDP) supported by a National Health Financing Plan (NHFP). These two documents play a critical role in driving internal resource mobilisation. At the same time, public health emergencies are surging, rising 41%—from 152 in 2022 to 213 in 2024—exposing severe under-resourcing of health infrastructure and workforce. Recurring outbreaks (Mpox, Ebola, cholera, measles, Marburg…) alongside effects of climate change and humanitarian crises in Eastern DRC, the Sahel, and Sudan, are overwhelming systems stretched by chronic underfunding. The situation is worsened by Africa’s heavy dependency with over 90% of vaccines, medicines, and diagnostics being externally sourced—leaving countries vulnerable to global supply chain shocks. Health worker shortages persist, with only 2.3 professionals per 1,000 people (below the WHO’s recommended 4.45), and fewer than 30% of systems are digitized, undermining disease surveillance and early warning. Without decisive action, Africa CDC projects the continent could reverse two decades of health progress, face 2 to 4 million additional preventable deaths annually, and a heightened risk of a pandemic emerging from within. Furthermore, 39 million more Africans could be pushed into poverty by 2030 due to intertwined health and economic shocks. This is not just a sectoral crisis—it is an existential threat to Africa’s political, social, and economic resilience, and global stability. In response, African leaders, under Africa CDC’s stewardship, are advancing a comprehensive three-pillar strategy centered on domestic resource mobilization, innovative financing, and blended finance. more

Namibia: National Guidelines for Medicine Safety Surveillance

Ministry of Health and Social Services (MOHSS) (2017) C2

Accessed November, 2017

Zambia Essential Medicines List (ZEML) 05
recommended

Ministry of Health, Zambia (2020) C1

2020 Version

Towards Access 2030. WHO Medicines and Health Products Programme Strategic Framework 2016-2030

(2017) C_WHO

National Drug Distribution Guidelines 2nd Edition 2012

Federal Ministry of Health, Nigeria (2012) C1

Essential Medicines and Health Supplies List for Uganda (EMHSLU) 2016

Ministry of Health Uganda (2016) C1

Swaziland: Guidelines on Import and Export Procedures for Medicines

Ministry of Health, Kingdom of Swaziland (2016) C2